[1. Hutchinson M, et al. Intravenous therapy for the treatment of multiple sclerosis. Future Prescriber 2008; Volume 8(1): 15.10.1002/fps.4]Search in Google Scholar
[2. Weinshenker BG, et al. The natural history of multiple sclerosis: a geographic based study. I. Clinical course and disability. Brain. 1989 Feb; 112 (Pt 1): 133-46.10.1093/brain/112.1.133]Search in Google Scholar
[3. Cree B. Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 2006; 12: 171–178.10.1097/01.nrl.0000204859.15501.6b]Open DOISearch in Google Scholar
[4. Hohlfeld R, Wekerle H. Drug Insight: using monoclonal antibodies to treat multiple sclerosis. Nat Clin Pract Neurol 2005; 1: 34–44.10.1038/ncpneuro0016]Search in Google Scholar
[5. Jakimovski D, et al. Interferon β for Multiple Sclerosis. Cold Spring Harb Perspect Med 2018 Jan 8. (Epub ahead of print).10.1101/cshperspect.a032003]Search in Google Scholar
[6. Patti F, Optimizing the benefits of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010 Feb; 4: 1-9.10.2147/PPA.S8230]Search in Google Scholar
[7. Frohman E, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist. 2002 Jul; 8(4): 227-36.10.1097/00127893-200207000-00003]Open DOISearch in Google Scholar